Forensic · INMB
Inmune Bio
Top signals
Officer Departure Recent
C-suite officer departure (Item 5.02) in the last 6 months.
+4
Bear case preview · free
Inmune Bio's low red-flag score of 4/100 is anchored primarily to a recent officer departure in the C-suite within the last six months, flagged under Item 5.02 disclosure requirements. While a single executive transition does not inherently signal distress, it warrants scrutiny given the biotech sector's sensitivity to leadership continuity, particularly if the departing officer held critical functions in clinical development or investor relations. Monitor the next 30-90 days for any announcements regarding strategic refocusing, clinical trial delays, or secondary offerings that might contextualize the departure as part of broader operational challenges.
↑ That's free. The $9 report goes deeper: every filing cited by accession number, 36-month chronology, what to watch next.
What we checked
✓ Red flags · 36mo
1 8-K event (bankruptcy, delisting, restatement, auditor, officer)
✓ Cyber · 12mo
0 Item 1.05 disclosures + buried-cyber scan
✓ Dilution · 24mo
0 S-3 + 424B5 filings
✓ Buried events
Item 8.01 sections classified for hidden material disclosures
$9
· one-time · emailed in under a minute
The full bear case on INMB
Plain-English brief. Every signal cited to the exact SEC filing. 36-month chronology. What changes next.
✓ No-signals refund: if the algorithm finds zero red flags on your ticker, reply "refund" and I send the $9 back same day. No questions.
Not ready to buy? Get a free preview by email instead
We'll email you the top 3 signals on INMB + a discount code for the full report. No subscription, no spam.
Score another ticker
Not investment advice. Every signal grounded in a specific SEC filing. Companies may respond via info@filingfirehose.com.